The role of heart failure pharmacotherapy after left ventricular assist device support

Heart Fail Clin. 2014 Oct;10(4):653-60. doi: 10.1016/j.hfc.2014.07.008. Epub 2014 Aug 14.

Abstract

Left ventricular assist devices (LVADs) are an increasingly common treatment for end-stage systolic heart failure. However, there are limited data on how to best treat patients pharmacologically after LVAD implantation, resulting in uncertainty about which heart failure medications provide the most benefit. Still, some evidence exists that certain medical therapies can prevent remodeling and improve right ventricular and, possibly, left ventricular function. This article reviews the current literature for medical heart failure therapy in LVAD patients, and possible future treatment strategies.

Keywords: Heart failure; Left ventricular assist device; Mechanical circulatory support; Medical therapy; Review.

Publication types

  • Review

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Heart Failure / complications
  • Heart Failure / drug therapy*
  • Heart-Assist Devices*
  • Humans
  • Hypertension / complications
  • Hypertension / drug therapy

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors